TY - JOUR
T1 - Actively targeted nanomedicines for precision cancer therapy
T2 - Concept, construction, challenges and clinical translation
AU - Gu, Wenxing
AU - Meng, Fenghua
AU - Haag, Rainer
AU - Zhong, Zhiyuan
N1 - Funding Information:
This work was supported by research grants from the National Natural Science Foundation of China (NSFC 51633005 , 51761135117 , 51773146 , 51861145310 ) and the Deutsche Forschungsgemeinschaft (DFG).
Publisher Copyright:
© 2020 Elsevier B.V.
PY - 2021/1/10
Y1 - 2021/1/10
N2 - The development of targeted nanomedicines for cancer therapy has been an utmost focus of research across different fields including materials science, nanotechnology, biotechnology, pharmaceutics, and clinical medicine. Vehicle-mediated, enhanced and tumor-selective delivery is deemed as a powerful tool to boost the efficacy and meanwhile minimize the off-target effect of potent chemo drugs, and to potentiate biopharmaceuticals such as nucleic acids (DNA, siRNA, miRNA, mRNA, CRISPR/Cas9, etc.), proteins and peptides that poorly penetrate the cell membrane on their own while having explicit effects intracellularly. The targeted nanomedicines may further provide imminent treatments for intractable brain tumors by transporting drugs across the blood-brain barriers, multi-drug resistant (MDR) tumors by evading the MDR pathways, metastatic tumors by inhibiting migratory tumor cells, and relapsed tumors by eliminating the cancer stem cells. The preclinical and clinical investigations demonstrate the clear benefits of targeted nanomedicines in treating advanced solid and hematological malignancies. In this review, we highlight the design and construction of conceptually interesting and clinically viable actively targeted cancer nanomedicines containing small molecular drugs, nucleic acid drugs, or protein/peptide drugs, discuss their pros and cons, and give perspectives on the future developments and clinical translation. We are convinced that with collaborative research and development across the disciplines, actively targeted cancer nanomedicines will make a breakthrough and become an indispensable platform for precision cancer therapy.
AB - The development of targeted nanomedicines for cancer therapy has been an utmost focus of research across different fields including materials science, nanotechnology, biotechnology, pharmaceutics, and clinical medicine. Vehicle-mediated, enhanced and tumor-selective delivery is deemed as a powerful tool to boost the efficacy and meanwhile minimize the off-target effect of potent chemo drugs, and to potentiate biopharmaceuticals such as nucleic acids (DNA, siRNA, miRNA, mRNA, CRISPR/Cas9, etc.), proteins and peptides that poorly penetrate the cell membrane on their own while having explicit effects intracellularly. The targeted nanomedicines may further provide imminent treatments for intractable brain tumors by transporting drugs across the blood-brain barriers, multi-drug resistant (MDR) tumors by evading the MDR pathways, metastatic tumors by inhibiting migratory tumor cells, and relapsed tumors by eliminating the cancer stem cells. The preclinical and clinical investigations demonstrate the clear benefits of targeted nanomedicines in treating advanced solid and hematological malignancies. In this review, we highlight the design and construction of conceptually interesting and clinically viable actively targeted cancer nanomedicines containing small molecular drugs, nucleic acid drugs, or protein/peptide drugs, discuss their pros and cons, and give perspectives on the future developments and clinical translation. We are convinced that with collaborative research and development across the disciplines, actively targeted cancer nanomedicines will make a breakthrough and become an indispensable platform for precision cancer therapy.
KW - Active targeting
KW - Biopharmaceuticals
KW - Cancer therapy
KW - Clinical translation
KW - Nanomedicines
KW - Targeted delivery
KW - n/a OA procedure
UR - http://www.scopus.com/inward/record.url?scp=85092243255&partnerID=8YFLogxK
U2 - 10.1016/j.jconrel.2020.10.003
DO - 10.1016/j.jconrel.2020.10.003
M3 - Article
SN - 0168-3659
VL - 329
SP - 676
EP - 695
JO - Journal of controlled release
JF - Journal of controlled release
ER -
